Objective: Peripheral arterial disease (PAD) affects nearly 8.5 million patients in the United States according to the Centers for Disease Control and Prevention. Although lifestyle modification and medical management can delay the rate of disease progression, approximately 5% of patients with PAD will eventually require revascularization. The most common complication of lower extremity bypass is surgical site infection (SSI), which can lead to prolonged hospital stays, additional procedures, and additive patient and hospital costs.
Methods: We analyzed data from 10,741 patients with PAD treated with open femoropopliteal bypass surgery collected from the National Surgical Quality Improvement Program (NSQIP) database from 2010 to 2016 using International Classification of Diseases and Current Procedural Terminology codes. c 2 tests and t-tests were used to compare preoperative risk factors. Logistic regression analysis was then used to correct for preoperative comorbidities. Analysis of strength of our model was performed using Hosmer-Lemeshow goodness of fit testing and receiver operating characteristic analysis.
Results: Overall in the NSQIP cohort, we found that the overall rate of any infection was 9.3%. Reported wound disruption was 1.7%. Superficial SSIs made up most of this number at 6.6%; deep incisional SSI was 2.2%, and organ/space SSI was 0.6%. Predictably, overall the strongest predictor of any SSI was the presence of diabetes, with a 29.5% increase in SSI with non-insulin dependence (adjusted odds ratio [aOR], 1.29; 95% confidence interval [CI], 1.09-1.54; P ¼ .004) and a 68.3% increase with insulin dependence (aOR, 1.68; 95% CI, 1.44-1.96; P < .001). A history of chronic obstructive pulmonary disease was the second most important factor with a 43.6% increase in incidence of SSI (aOR, 1.44; 95% CI, 1.21-1.71; P < .001). Surprisingly, a history of smoking within 1 year did not dramatically increase the risk of SSI, with only a 19.4% increase in incidence (aOR, 1.19; 95% CI, 1.04-1.36; P ¼ .01).
Conclusions: Femoropopliteal bypass is the "gold standard" for treatment of femoral PAD. With the prevalence of endovascular treatment, analysis of the most recent NSQIP data finds some interesting trends as to risk factors for development of SSI with femoropopliteal bypass. The overall rate of SSI is much higher than in other reported studies in the literature at 9.3%, which might be a contribution of endovascular treatment for healthier patients.
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